Citadel Advisors
CAI

Citadel Advisors’s Caris Life Sciences CAI Stock Holding History

Citadel Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Buy
297,855
+220,045
+283% +$3.94M ﹤0.01% 4616
2026
Q1 		$1.39M Sell
77,810
-3,036,146
-98% -$66.4M ﹤0.01% 6890
2025
Q4 		$84M Buy
+3,113,956
New +$87.7M 0.01% 974
2025
Q3 		– Sell
-341,570
Closed -$10.9M – 14581
2025
Q2 		$9.13M Buy
+341,570
New +$9.21M ﹤0.01% 3160

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citadel Advisors's CAI Position: Q2 2026 in Review

Citadel Advisors increased its Caris Life Sciences (CAI) stake by 283% in Q2 2026, buying an estimated $3.94M and bringing the position to 297,855 shares worth $5.31M. The position accounts for ﹤0.01% of the portfolio, ranked #4616.

Citadel Advisors first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $84M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Citadel Advisors held 297,855 shares of Caris Life Sciences worth $5.31M as of Q2 2026.
  • Citadel Advisors bought 220,045 Caris Life Sciences shares in Q2 2026, an estimated $3.94M.
  • Caris Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4616 holding.
  • Citadel Advisors first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Citadel Advisors's Caris Life Sciences position peaked at $84M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.